CABA
Closed
Cabaletta Bio Inc
1.56
+0.04 (+2.63%)
Last Update: 01 Jul 2025 23:15:00
Yesterday: 1.52
Day's Range: 1.51 - 1.615
Send
sign up or login to leave a comment!
When Written:
8.27
Cabaletta Bio Inc is a clinical-stage biotechnology company that is focused on the discovery and development of engineered T cell therapies for the treatment of B cell-mediated autoimmune diseases. The company was founded in 2017 and is headquartered in Philadelphia, Pennsylvania.
Cabaletta Bio's lead product candidate is DSG3-CAART, which is a chimeric autoantibody receptor T cell therapy that is designed to selectively eliminate the B cells that produce autoantibodies that attack the desmoglein 3 (DSG3) protein, which is a key component of the skin and mucous membranes. DSG3-CAART is currently being evaluated in a Phase 1 clinical trial for the treatment of patients with mucosal pemphigus vulgaris, a rare autoimmune disease that affects the skin and mucous membranes.
In addition to DSG3-CAART, Cabaletta Bio is also developing other product candidates that target B cell-mediated autoimmune diseases, including mucosal pemphigoid, bullous pemphigoid, and IgA nephropathy. The company's technology platform is based on the use of chimeric autoantibody receptor T cells (CAARTs), which are engineered T cells that express a chimeric antigen receptor (CAR) that is designed to recognize and eliminate B cells that produce disease-causing autoantibodies.
Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
Cabaletta Bio's lead product candidate is DSG3-CAART, which is a chimeric autoantibody receptor T cell therapy that is designed to selectively eliminate the B cells that produce autoantibodies that attack the desmoglein 3 (DSG3) protein, which is a key component of the skin and mucous membranes. DSG3-CAART is currently being evaluated in a Phase 1 clinical trial for the treatment of patients with mucosal pemphigus vulgaris, a rare autoimmune disease that affects the skin and mucous membranes.
In addition to DSG3-CAART, Cabaletta Bio is also developing other product candidates that target B cell-mediated autoimmune diseases, including mucosal pemphigoid, bullous pemphigoid, and IgA nephropathy. The company's technology platform is based on the use of chimeric autoantibody receptor T cells (CAARTs), which are engineered T cells that express a chimeric antigen receptor (CAR) that is designed to recognize and eliminate B cells that produce disease-causing autoantibodies.
Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
(0)
(0)
Send
sign up or login to leave a comment!!